COVINGTON, Ky., Oct. 12, 2023 /PRNewswire/ — Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will participate in the 3rd Annual Needham Private Biotech Company Virtual 1×1 Forum. The conference will be held virtually, from October 17-18, 2023.
Scott Shively, CEO and President of Bexion Pharmaceuticals, and Joyce LaViscount, Chief Financial Officer of Bexion Pharmaceuticals, will attend the conference.
About Bexion Pharmaceuticals
Bexion Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) with potential portfolio expansion opportunities in other cancers and broader neuropathic pain indications. Bexion currently has three clinical trials open for enrollment.
Solebury Strategic Communications
SOURCE Bexion Pharmaceuticals, Inc.